Better Medicines for Children, A DIA/EFGCP Conference

Plan ahead and join us to reflect on the importance of two major headways that are currently affecting Paediatric research: Innovative approaches to Drug Development and impact of the current environment on the Regulatory and Research Infrastructure

Back to Agenda

Session 3: Innovation in Pediatric Development: Formulation, Trial Design and Real World Data

Session Chair(s)

Siri Wang

Scientific Director; PDCO delegate

Norwegian Medical Products Agency, Norway

Session 3: Innovation in Pediatric Development: Formulation, Trial Design and Real World Data

Speaker(s)

Beyond Tablets and Liquids – Update on new Concepts for Paediatric Formulations

Joerg Breitkreutz

Heinrich-Heine-University Düsseldorf, Institute of Pharmaceutics and Biopharmace, Germany

Professor of Pharmaceutical Technology

Innovative Trial Designs - How Much Can We Use Data from Adults?

Anja Schiel, PhD

Norwegian Medicines Agency (NoMA), Norway

Special Advisor, Lead Methodologist; Leader international HTA (iHTA) NoMA

Title Registries, Apps, Wearables - How Does Real World Data Change the Way We Do Studies?

Elin Haf Davies, BSN, PhD

aparito, United Kingdom

Founder/CEO

Have an account?

Better Medicines for Children, A DIA/EFGCP Conference

Session 3: Innovation in Pediatric Development: Formulation, Trial Design and Real World Data

Session Chair(s)

Siri Wang

Speaker(s)

Beyond Tablets and Liquids – Update on new Concepts for Paediatric Formulations

Innovative Trial Designs - How Much Can We Use Data from Adults?

Title Registries, Apps, Wearables - How Does Real World Data Change the Way We Do Studies?

Be informed and stay engaged.